Citation APA
Schuster, M., Zijlstra, J. J., Casasnovas, R. O., Vermaat, J. J., Kalakonda, N., Goy, A., Choquet, S., Van Den Neste, E., Hill, B., Thieblemont, C., Cavallo, F., De la Cruz, F., Kuruvilla, J., Hamad, N., Jäger, U., Caimi, P., Gurion, R., Warzocha, K., Bakhshi, S., Sancho, J. M., Follows, G., Egyed, M., Offner, F., Vassilakopoulos, T., Samal, P., Ku, M., Ma, X., Corona, K., Chamoun, K., Shah, J., Shacham, S., Kauffman, M., Canales, M., & Maerevoet, M. (2022). Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study. Clinical Lymphoma, Myeloma and Leukemia. doi:10.1016/j.clml.2021.12.016
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/339000